Physician profile

Martin E Menosky

Family Medicine · Athens, OH

NPI 1780660886

$1,169.42

in general payments reported to CMS, 2019-2025

20 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $346.91 2019-2020
Astrazeneca Pharmaceuticals LP $199.39 2019-2020
Allergan, INC. $147.30 2019
Amgen INC. $66.11 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $61.37 2019-2020
Mylan Specialty L.P. $44.43 2019-2020
Orexo US, INC. $39.38 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $36.47 2019
Pfizer INC. $35.48 2020
Jazz Pharmaceuticals INC. $26.35 2019-2020
Lilly USA, LLC $25.65 2019
Antares Pharma, INC. $24.67 2019
Janssen Pharmaceuticals, INC $24.46 2019-2020
Scilex Pharmaceuticals INC. $18.24 2019
Avanir Pharmaceuticals, INC. $13.74 2019
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Amarin Pharma, INC. $12.55 2019
Merck Sharp & Dohme LLC $12.14 2019
Collegium Pharmaceutical, INC. $12.13 2019
Glaxosmithkline, LLC. $11.66 2019
Teva Pharmaceuticals USA, INC. $10.99 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Martin E Menosky

$1,169.42

in general payments reported 2019-2025

Years
2019-2020
Top company
Novo Nordisk INC

https://glasscript.com/doctor/217263/martin-e-menosky

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.